Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2008 Feb 23.

Published in final edited form as: Neuroscience. 2006 Dec 11;144(4):1436–1446. doi: 10.1016/j.neuroscience.2006.11.002

Table 2.

Region-Specific ED₅₀ Values for MNX and Potency Ratios after Single or Repeat Morphine

	ED₅₀ (95 % CL)^a		Potency Ratio (95% CL)
Injection Site	Single Morphine	Repeat Morphine	Single vs Repeat at Same Site	Single vs ICV Single	Repeat vs ICV Repeat
ICV	1961 (556 – 6903)	442 (170 – 1149)	4.4^* (0.9 – 21.6)	--------	--------
NAC	109 (46.1 – 259)	34.1 14.5 – 80.4	3.2 (0.9 – 10.8)	17.9^* (3.9 – 82.5)	12.9^* (3.6 – 46.7)
BNST	290 (121 – 696)	51.0 (17.2 – 151)	5.7^* (1.4 – 22.9)	6.8^* (1.5 – 31.3)	8.7^* (2.0 – 36.8)
CeA	355 (144 – 873)	136 (65.6 – 281)	2.6 (0.8 – 8.3)	5.5^* (1.2 – 25.9)	3.2 (1.0 – 10.8)
IPAC	> 500	> 500	--------	--------	--------

^a

Values reflect ED₅₀ in ng, 95 % confidence limits (CL) in parentheses

^*

p<0.05 significant potency ratio as determined by method of Litchfield and Wilcoxon (Tallarida and Murray, 1987)